DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo

Cubist Pharmaceuticals (NASDAQ: CBST)



company name or ticker
Company Photos
(Click to zoom)

Cubist Pharma's Antibiotics Portfolio Holds Promise - Analyst Blog

Cubist Pharma Reports Publicant of Pivotal Data from SIVEXTRO ESTABLISH-2 Trial

1 Stock Fighting the Rise of Deadly Superbugs

With the official FDA approval of Durata's antibiotic treatment Dalvance now in the bag, the company is projected to see stellar top-line growth next year. Here is what you need to know about this small-cap biotech.

2 Growth Stocks You Need to Know About

Biotech companies with newly approved drugs can offer investors nearly unprecedented levels of growth in terms of earnings per share. Here are two biotechs with pending regulatory approvals worth watching.

Alnylam Up on Narrower-than-Expected Q1 Loss - Analyst Blog

Alnylam Up on Narrower-than-Expected Q1 Loss - Analyst Blog

2014 FDA Drug Approval Calendar

Should Basilea Pharmaceutica Be Trading At Twice This Price?

CBS Earnings Preview: Falling Expectations?

3 Biotech Stocks Making Big Moves Last Week

Here are the reasons behind last week's big move in United Therapeutics (UTHR), Cubist Pharmaceuticals (CBST), and Incyte Corporation (INCY).

CBST Makes Bullish Cross Above Critical Moving Average

See More Articles...